Defunct Company
Total Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
84
NCT01056029
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jan 31, 2010
Completion: Aug 31, 2013
NCT01777594
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Phase: Phase 2
Start: Jan 31, 2013
Completion: Mar 31, 2015
NCT01734681
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
Start: May 31, 2013
Completion: Jan 31, 2015
NCT02067156
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
Start: Feb 28, 2014
Completion: Feb 28, 2017
NCT02381236
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
Start: Feb 29, 2016
NCT02607553
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Start: Jun 30, 2016
NCT02876003
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
Start: Sep 30, 2016
Completion: Oct 31, 2020